Bio-Rad Laboratories, a global provider of life science research and clinical diagnostics products, has improved its Liquichek quality control product portfolio with the launch of an enhanced version of its Liquichek Opiate Control.

This enhanced version of Liquichek

Opiate Control includes updated fentanyl target levels optimized for clinically relevant cutoffs across chemistry major platforms. This ensures laboratories can meet evolving testing requirements with confidence and precision.

Bio-Rad’s Liquichek Opiate Control contains eight opioid drugs or drug metabolites, at concentrations above and below assay cutoffs as recommended by the U.S. Substance Abuse and Mental Health Services Administration (SAMHSA), other agencies, or reagent manufacturers. The control is tested by GC/MS, LC/MS/MS and other methods to confirm the recovery of drug concentration, with representative values provided for screening and confirmatory methods.

Liquichek Opiate Control streamlines workflows and delivers validated precision at clinically relevant cut-offs, enabling laboratories to confidently report results and strengthen their ability to respond to the opioid crisis.

Liquichek Opiate Control is available now.
Visit bio-rad.com

Digital issue: Please click here for more information